Ambu A/S
AMBFF
Other OTC9.90
USD
- -
- -
ISIN
DK0060946788
Return %
Stock
S&P500
1Y
-34.70
26.53
3Y
-31.01
76.60
5Y
-73.60
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Britt Meelby Jensen
- Full Time Employees
- 5,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Baltorpbakken 13 Ballerup Denmark 2750
- IPO Date
- May 19, 2017
- Website
- ambu.com
- Similar Companies
- Business
- Ambu A/S develops, manufactures and markets single-use endoscopy solutions, diagnostic and life-supporting equipment to hospitals, private practices and rescue services worldwide; its core offerings span Endoscopy Solutions, including single-use flexible and semi-rigid endoscopes, video laryngoscopes and integrated systems such as aScope 5 Broncho, aScope 5 Uretero, aScope 5 Cysto HD cysto-nephroscopes, aScope Gastro, SureSight Connect and aBox 2 across pulmonology, urology, ear-nose-throat (ENT) and gastroenterology (GI) segments; and Anesthesia & Patient Monitoring products, comprising ventilation devices like the legacy Ambu bag resuscitator, disposable electrodes for ECG and neurophysiological mapping, and patient monitoring solutions. The company operates globally with North America contributing over 50% of revenue, followed by Europe and Rest of World (Asia Pacific, Latin America), through production sites in the USA, China, Malaysia and Mexico; it is headquartered in Ballerup, Denmark, and was founded in 1937. Ambu pursues strategic growth via its ZOOM AHEAD initiative launched in 2025, raising long-term organic revenue CAGR targets to 11-13% through FY 2029/30 (Endoscopy Solutions at 15-20%, Anesthesia & Patient Monitoring at 3-5%) and EBIT margin to +20%, building on the ZOOM IN strategy's success in achieving debt-free status, double-digit growth and strong cash flow; recent advancements include FDA clearance for aScope 5 Cysto HD in Q3 2024/25, expansion of SureSight Connect to pediatric patients, launch of the Ambu Recircle Program for endoscope recycling in key markets (UK, US, Germany, France) and plans for acquisitions in FY 2025/26 following financial stabilization.
Ambu A/S (AMBBY) Q1 2026 Earnings Call Transcript
Ambu A/S (AMBBY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ambu A/S (AMBBY) Shareholder/Analyst Call Prepared Remarks Transcript
Ambu A/S (AMBBY) Q4 2025 Earnings Call Transcript
Ambu upgraded to Buy from Hold at Nordea
Ambu A/S (AMBFF) Q4 2024 Earnings Call Transcript
Ambu A/S (AMBFF) Q1 2024 Earnings Call Transcript
Ambu A/S (AMBFF) Q2 2023 Earnings Call Transcript
Ambu A/S (AMBFF) Q4 2022 Earnings Call Transcript